We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food and Drug Administration’s … NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials
We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment options that … New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus
The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates the levels of … Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment
Advocating for your own best care includes raising the possibility of joining a clinical trial with your healthcare provider. Here’s more on how: It is important for individuals who are considering participation in a trial to understand what will be involved. The National Institutes of Health (NIH) asking the healthcare team overseeing the study about … Ask About Clinical Trial Opportunities
Up to 95% of lupus patients report pain and fatigue caused by the disease. To explore ways to fix this, a research team led by Dr. Cynthia Aranow at The Feinstein Institutes for Medical Research studied whether lessening inflammation in patients with lupus would also lessen pain and fatigue. In this study, she and her … LuCIN Investigators Show that Stimulating the Vagus Nerve in Lupus Patients Decreases Pain and Fatigue
Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm … Promising New Lupus Treatments Highlighted ACR Annual Meeting
PPD, Inc. issued a press release today announcing its collaboration with the Lupus Research Alliance affiliate Lupus Therapeutics to optimize lupus clinical research among its pharmaceutical and biotech clients. As a contract research organization, PPD helps its clients design and implement clinical trials. PPD expects to gain from Lupus Therapeutics’ deep clinical trial design expertise … Lupus Therapeutics Collaborating with PPD to Accelerate Lupus Clinical Research
Videotape of 8.24.20 Learn from Lupus Zoom Webcast Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immunocompromised. In light of COVID-19, … Watch Webcast Video: Redefining Lupus Trials Amid COVID-19 and Beyond
African-Americans are more likely to develop lupus than Caucasians, but less likely to take part in clinical trials of the disease. However, a new study showed that several simple steps, such as providing transportation and flexible scheduling, may allow more African-Americans to participate in trials. The study was conducted by top lupus experts including Dr. … New Study Presents Strategies That Helped African-Americans Take Part In Lupus Trials
New research published in Arthritis and Rheumatology shows that peripheral nervous system (PNS) disease is an important part of neuropsychiatric lupus with significant effects on quality of life. The peripheral nervous system is the network that sends signals between the brain and spinal cord (the central nervous system) with all the other parts of the … Lupus Has Nerve Shows Large International Study
The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration. As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review of drugs to … Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA
The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly encouraged by the positive results reported for several potential new treatments that may help people with lupus. “The foundational work the Lupus Research Alliance and others have supported is beginning to bear fruit with potential therapies like anifrolumab, … Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments